Faeth Therapeutics, Inc.
FTH Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$16.83
KIRA · Stoqly’s AI analyst, in plain words
- Faeth Therapeutics, Inc. lost $21.1M in fiscal 2025.
- Free cash flow was −$20.5M in fiscal 2025, — of revenue.
Market cap
$95.0M
P/E
—
Revenue
—
Net income
−$21.1M
Free cash flow
−$20.5M
Operating margin
—
Faeth Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$21.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Faeth Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Faeth Therapeutics, Inc.
- CIK
- 0001829802
Faeth Therapeutics, Inc. · FTH
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$36.8M | −$48.6M | −$34.1M | −$30.2M | −$21.1M |
| Diluted EPS | −$1.33 | −$1.58 | −$1.22 | −$24.01 | −$16.72 |
| Cash | |||||
| Cash from operations | −$30.3M | −$39.0M | −$32.0M | −$24.7M | −$20.5M |
| Capital expenditure | $2.0M | $0.3M | $0.2M | $0.1M | $0.0M |
| Free cash flow | −$32.3M | −$39.3M | −$32.2M | −$24.8M | −$20.5M |
| Share buybacks | — | — | $10.4M | — | — |
| Share count change | 1,618.9% | 10.8% | −9.0% | −95.5% | 0.4% |
| Debt and strength | |||||
| Cash and short-term investments | $148M | $107M | $65.8M | $41.3M | $21.2M |
| Shareholders' equity | $147M | $103M | $64.9M | $38.4M | $18.6M |
| Current ratio | 30.4x | 12.0x | 11.9x | 7.7x | 5.1x |
| Interest coverage | −55.9x | −229.2x | −257.4x | −362.4x | −696.5x |
| Returns and quality | |||||
| Return on equity | −81.7% | −38.9% | −40.5% | −58.4% | −74.0% |
| Return on tangible equity | −25.1% | −47.0% | −52.5% | −78.6% | −113.4% |
| Altman Z'' | 24.3 | 4.5 | −0.9 | −12.6 | −37.4 |
Insiders bought, 12 months
$2.5M
4 insiders
Insiders sold, 12 months
$2.0M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Faeth Therapeutics, Inc. · FTH
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $16.83 a share, the company is worth $95.0M.
Source: SEC EDGAR XBRL filings (CIK 0001829802). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.